This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

CDP 323

UCB SA

Drug Names(s): CDP323

Description: CDP323 is an orally active small molecule a4-integrin inhibitor. CDP323 blocks the binding of vascular cell adhesion molecule 1 (VCAM-1) binding to VLA-4.

Deal Structure: October 2006: UCB and Biogen announced a global collaboration to jointly develop and commercialize CDP323 for the treatment of relapsing-remitting multiple sclerosis (MS) and other potential indications.

Under terms of the agreement, UCB will receive upfront and additional payments for development and commercial milestones in excess of $200 million US dollars. Furthermore Biogen Idec will contribute significantly to clinical costs for Phase II and Phase III studies. All commercialization costs and profits will be shared equally.

Partners: Biogen, Inc.


CDP 323 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug